 |
Looking for funding
in 2010?
Network with Leading Investors & Analysts |
- Baker and Mc Kenzie
- Burrill & Company
- Cic - Vizille Capital Finance
- Esperante
- HBM Partners
- Index Ventures
|
- Jina Ventures Inc
- Kurma Life Science Partners
- Lombard Odier
- Merck Serono Ventures
- Novartis Venture Fund
- NYSE Euronext
|
- Pictet & Cie
- Roche
- Sectoral Asset Management
- Seventure Partners
- Tilocor Life Sciences
- Ventech...
|
|
BioSquare 2010 Program Highlights – Life Science Investing Session
|
Conference links
|
|
The format of this session will be interactive round tables. Instead of listening to experts, selected delegates
will have the opportunity to directly interact with them, in a best practice sharing experience.
|
“Emerging biotech markets: opportunities, threats and realities”
Monday February 1st, 2010 - 08:30 - 09:40
Emerging markets represent undoubtedly large commercial opportunities for biotech and pharma companies: in 2010 China is poised to become the world’s second largest economy. But could China, India, Brasil or other emerging markets also develop as large biotech hubs and play a leading rôle as R&D players? What about their ability to become competitors as site locations for young biotech companies? Could these countries be the new sources for biosimilar drugs? This panel discussion will review these issues in detail with leading biotech investors, financial analysts and industry representatives having concrete on the ground expertise in these emerging countries.
Key Speakers: - Michael Sjöström, Chief Investment Officer, Sectoral Asset Management
- Matthias Fehr, Investment Advisor Public Equity Team, HBM Partners
- Delphine Le Louët, Pharma analyst, Lombard Odier
“Biotech companies: the emergence of a new business model with the pharma industry?”
Monday February 1st, 2010 - 09:55 - 11:05
With increasingly risk averse investors, larger R&D development costs and the resulting lack of funding, is the dream of many biotech companies of becoming fully integrated pharma companies such as Gilead, Biogen or Actelion still a feasable? Or are we gradually witnessing a change in the business model of biotech companies towards a split of tasks among pharma companies, development companies and biotech companies? In such a model, biotech companies will increasingly and uniquely focus their activities on preclinical and early development work? Biotech investors, Pharma venture funds, VC and biotech and pharma companies will discuss during this trends and analyse what this shift will mean for them and the industry.
Key Speakers: - Roel Buthuis, Head of Merck Serono Ventures, Merck Serono
- David Freedmann, Partner, Baker and Mckenzie
- Pascal Frank, Biotech and Pharma analyst, Pictet & Cie
- Stefan Catsicas, co-founder, Tilocor Life Sciences
- Francesco de Rubertis, Partner, Index Ventures
|
Register now for two days of intense networking!
 |
|
For more information, please contact: |
|
